Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

BUY
$47.98 - $54.4 $13,722 - $15,558
286 Added 7.19%
4,264 $231,000
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $7,708 - $9,198
-159 Reduced 3.84%
3,978 $204,000
Q3 2023

Oct 19, 2023

BUY
$57.89 - $64.73 $239,490 - $267,788
4,137 New
4,137 $240,000
Q3 2022

Nov 02, 2022

SELL
$0.13 - $76.84 $22 - $13,293
-173 Reduced 3.58%
4,655 $331,000
Q2 2022

Jul 12, 2022

BUY
$72.62 - $79.98 $66,156 - $72,861
911 Added 23.26%
4,828 $372,000
Q1 2022

Apr 18, 2022

SELL
$61.48 - $73.72 $7,685 - $9,215
-125 Reduced 3.09%
3,917 $286,000
Q4 2021

Jan 24, 2022

SELL
$53.63 - $62.52 $38,774 - $45,201
-723 Reduced 15.17%
4,042 $252,000
Q3 2021

Nov 02, 2021

BUY
$59.17 - $69.31 $32,661 - $38,259
552 Added 13.1%
4,765 $282,000
Q2 2021

Jul 29, 2021

BUY
$61.91 - $67.42 $11,391 - $12,405
184 Added 4.57%
4,213 $281,000
Q1 2021

May 12, 2021

SELL
$59.34 - $66.74 $222,406 - $250,141
-3,748 Reduced 48.19%
4,029 $254,000
Q1 2021

Apr 29, 2021

BUY
$59.34 - $66.74 $461,487 - $519,036
7,777 New
7,777 $1.49 Million
Q4 2020

Jan 29, 2021

SELL
$57.74 - $65.43 $237,195 - $268,786
-4,108 Closed
0 $0
Q3 2020

Oct 13, 2020

BUY
$57.43 - $63.64 $235,922 - $261,433
4,108 New
4,108 $248,000
Q1 2019

Apr 23, 2019

SELL
$45.12 - $53.8 $186,074 - $221,871
-4,124 Closed
0 $0
Q4 2018

Jan 28, 2019

SELL
$48.76 - $63.23 $14,628 - $18,969
-300 Reduced 6.78%
4,124 $214,000
Q2 2018

Aug 07, 2018

BUY
$50.53 - $62.98 $101 - $125
2 Added 0.05%
4,424 $244,000
Q1 2018

May 08, 2018

BUY
$59.92 - $68.98 $65,492 - $75,395
1,093 Added 32.83%
4,422 $274,000
Q3 2017

Nov 08, 2017

BUY
$55.23 - $63.74 $183,860 - $212,190
3,329
3,329 $214,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Connecticut Wealth Management, LLC Portfolio

Follow Connecticut Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connecticut Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Connecticut Wealth Management, LLC with notifications on news.